On April 17, 2025, Tevogen Bio Holdings Inc. entered into a Master Services and Facilities Agreement with CD8 Technology Services LLC for specialized manufacturing support for its cell therapy products, with an initial term of 12 months. CD8 is associated with a significant shareholder of Tevogen.